Repeats from Monday with no changes
** Shares of Johnson & Johnson JNJ.N rise 1% to $153.42 on Mon ahead of its first quarter results due before the market open on Tues with investors focused on how the pharmaceutical giant is dealing with tariffs imposed by President Donald Trump
** Trump announced a 90-day freeze on some of his new tariffs but left in place 10% tariffs on most U.S. imports
** Analysts expect JNJ to report rev of ~$21.57 bln, flat from a year ago, and EPS of $2.59, down ~4.5% from a year ago
** Among 26 analysts that cover JNJ, avg rating is "BUY" and median PT is $169.50, per LSEG data
** JNJ's rev has exceeded expectations 7 times over the last 8 quarters, while EPS has met estimates every time
** JNJ is up 6.4% YTD compared with the S&P 500 health index .SPXHC, which is up just ~6%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。